Mr. Walden (for himself, Mr. Pallone, Mr. Burgess, and Mr. Gene Green of Texas) introduced the following bill; which was referred to the Committee on Energy and Commerce, Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed
To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.
Citations are generated automatically from bibliographic data
as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. House. FDA Reauthorization Act of 2017. H.R. 2430. 115th
Cong., 1st
sess., Reported in House July 11, 2017. https://www.govinfo.gov/app/details/BILLS-115hr2430rh.
APA
Congress, House of Representatives (2017, July 11). FDA Reauthorization Act of 2017 (H.R. 2430 (RH)). Retrieved from https://www.govinfo.gov/app/details/BILLS-115hr2430rh.
MLA
United States, Congress, House of Representatives. FDA Reauthorization Act of 2017. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-115hr2430rh. 115th Congress, H.R. 2430, Reported in House 11 Jul. 2017.
Bluebook
H.R.2430 - 115th Congress (2017-2018): FDA Reauthorization Act of 2017, H.R.2430, 115th Cong. (2017), https://www.govinfo.gov/app/details/BILLS-115hr2430rh.
